Asymmetric Triblock Copolymer Nanocarriers for Controlled Localization and pH-Sensitive Release of Proteins
Source abstract
Abstract
Designing nanocarriers to release proteins under specific conditions is required to improve therapeutic approaches, especially in treating cancer and protein deficiency diseases. We present here supramolecular assemblies based on asymmetric poly(ethylene glycol)-b-poly(methylcaprolactone)-b-poly(2-(N,Ndiethylamino)ethyl methacrylate) (PEG-b-PMCL-b-PDMAEMA) copolymers for controlled localization and pH-sensitive release of proteins. Copolymers self-assembled in soft nanoparticles with a core domain formed by PMCL, and a hydrophilic domain based on PEG mainly embedded inside, and the branched PDMAEMA exposed at the particle surface. We selected as model proteins to be attached to the nanoparticles bovine serum albumin (BSA) and acid sphingomyelinase (ASM), the latter being an ideal candidate for protein replacement therapy. The hydrophilic/hydrophobic ratio, nanoparticle size, and the nature of biomolecules are key factors for modulating protein localization and attachment efficiency. The predominant outer shell of PDMAEMA allows efficient pH-triggered release of BSA and ASM, and in acidic conditions >70% of the bound proteins were released. Uptake of protein-attached nanoparticles by HELA cells, together with low toxicity and pH-responsive release, supports such protein-bound nanoparticles as efficient stimuli-responsive candidates for protein therapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Polymer Surface Interaction Studies · Lipid Membrane Structure and Behavior
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemistry, University of Basel, Klingelbergstrasse 80, CH-4056 Basel, Switzerland
Funding
Swiss National Science Foundation · Swiss Nanoscience Institute, University of Basel
References (32)
Show source-provided references
1. Smales, C. M.; James, D. C.Therapeutic Proteins;Humana Press: 2005; Vol.308, pp1–16.10.1385/1592599222 ↗
2. 10.1002/jps.2205410.1002/jps.22054 ↗
3. 10.2217/nnm.13.1110.2217/nnm.13.11 ↗
4. 10.1016/S0168-3659(98)00116-310.1016/S0168-3659(98)00116-3 ↗
5. Jahanshahi M. · Afr. J. Biotechnol. · 2008 · 7 · 4926
6. 10.1186/1477-3155-11-2610.1186/1477-3155-11-26 ↗
7. 10.1016/j.biomaterials.2005.03.04510.1016/j.biomaterials.2005.03.045 ↗
8. 10.1016/j.biomaterials.2010.09.05210.1016/j.biomaterials.2010.09.052 ↗
9. 10.1039/b609879g10.1039/b609879g ↗
10. 10.1021/la062805b10.1021/la062805b ↗
11. 10.1016/j.jconrel.2014.08.01510.1016/j.jconrel.2014.08.015 ↗
12. Chu X.-P. · Int. J. Physiol. Pathophysiol. Pharmacol. · 2011 · 3 · 288
13. 10.1002/anie.20090006410.1002/anie.200900064 ↗
14. 10.1038/nnano.2009.34110.1038/nnano.2009.341 ↗
15. 10.1039/c2jm33434h10.1039/c2jm33434h ↗
16. 10.1016/j.biomaterials.2012.06.02010.1016/j.biomaterials.2012.06.020 ↗
17. 10.1016/j.biomaterials.2011.02.03410.1016/j.biomaterials.2011.02.034 ↗
18. 10.1016/j.febslet.2009.11.08310.1016/j.febslet.2009.11.083 ↗
19. 10.1124/jpet.107.13329810.1124/jpet.107.133298 ↗
20. 10.1002/macp.20100066110.1002/macp.201000661 ↗
21. 10.1021/ma060642s10.1021/ma060642s ↗
22. 10.1021/jp990251y10.1021/jp990251y ↗
23. 10.1021/bm500919z10.1021/bm500919z ↗
24. 10.1590/S1516-1439201400500003310.1590/S1516-14392014005000033 ↗
25. 10.1023/A:102018650584810.1023/A:1020186505848 ↗
26. 10.1146/annurev.ms.26.080196.00205310.1146/annurev.ms.26.080196.002053 ↗
27. 10.1529/biophysj.107.11278910.1529/biophysj.107.112789 ↗
28. Rahman M. · 2013 · 15 · 2110.1007/978-3-642-37555-2_2 ↗
29. 10.1016/j.jconrel.2006.11.02810.1016/j.jconrel.2006.11.028 ↗
30. 10.1016/S0168-3659(97)00059-X10.1016/S0168-3659(97)00059-X ↗
31. 10.1016/0167-4889(90)90028-C10.1016/0167-4889(90)90028-C ↗
32. 10.1002/mabi.20100039510.1002/mabi.201000395 ↗